The stock may react positively to the CAPTN-3 platform's preclinical data and extended cash runway, but traders should monitor for partnership developments on discontinued assets and upcoming clinical trial initiations for IM1240. The lack of revenue and continued losses remain key risks.
Price Chart
Executive Summary
Purple Biotech reported a significant net loss of $26.4 million for 2025, driven by a $20.5 million impairment charge related to the discontinuation of CM24 and NT219 programs. However, the company highlighted progress in its CAPTN-3 platform, including preclinical success and a $9.5 million cash position providing runway into 2027. Despite strong R&D advancements, the substantial loss and program discontinuations weigh on near-term fundamentals.
Key Financial Metrics
Key Facts
- Reported net loss of $26.4 million for 2025, up from $7.2 million in 2024, primarily due to a $20.5 million impairment charge on CM24 and NT219 programs
- Cash and cash equivalents totaled $9.5 million as of December 31, 2025, expected to fund operations into 2027
- Achieved key preclinical milestones for IM1240 and IM1305, including toxicology and manufacturing success, with data showing multi-arm anti-tumor activity
- R&D expenses decreased to $3.7 million in 2025 from $7.6 million in 2024 due to reduced clinical trial costs, despite increased CMC activities
- Company will not advance CM24 and NT219 without a strategic partner or additional financing
Financial Impact
Impairment charge of $20.5 million significantly increased net loss; R&D spending cut in half year-over-year excluding non-cash items
Risk Factors
- Dependence on future financing or partnerships to advance legacy programs CM24 and NT219
- High cash burn relative to market cap; any delay in CAPTN-3 development could pressure liquidity
- Preclinical data may not translate into clinical success; no near-term revenue catalysts
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3255440 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 9, 2026 23d ago | 6-K | $1.74 $1.55 | ▼ −11.21% | ▼ −10.71% | $1.51 (−13.22%) |
Sep 2, 2026 4w ago | 6-K | $1.98 $1.74 | ▼ −12.12% | ▼ −11.16% | $1.51 (−23.74%) |
Aug 10, 2026 7w ago | 6-K | $1.55 $1.56 | ▲ +0.65% | ▲ +1.05% | $1.51 (−2.58%) |
Aug 7, 2026 8w ago | 6-K | $1.43 $1.50 | ▲ +4.90% | ▲ +4.50% | $1.51 (+5.59%) |
May 15, 2026 20w ago | Press Release | $3.94 $2.88 | ▼ −26.90% | ▼ −27.87% | $1.51 (−61.68%) |
Apr 27, 2026 22w ago | 6-K | $4.59 $4.22 | ▼ −8.06% | ▼ −8.46% | $1.51 (−67.10%) |
Apr 23, 2026 23w ago | 6-K | $4.55 $4.23 | ▼ −7.03% | ▼ −8.51% | $1.51 (−66.81%) |
Mar 13, 2026 29w ago | Press Release | $4.10 $3.98 | ▼ −2.93% | ▼ −0.81% | $1.51 (−63.17%) |
Mar 13, 2026 29w ago | Press Release | $4.10 $3.98 | ▼ −2.93% | ▼ −0.81% | $1.51 (−63.17%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access